BPS-314d-MR ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	4

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03657095 (ClinicalTrials.gov)	December 10, 2018	18/5/2018	A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension	An Open-label Extension of BPS-314d-MR-PAH-302 in Pulmonary Arterial Hypertension Patients	Pulmonary Arterial Hypertension	Drug: Esuberaprost;Drug: Placebo	Lung Biotechnology PBC	NULL	Terminated	18 Years	85 Years	All	112	Phase 3	United States;Israel
2	NCT01966302 (ClinicalTrials.gov)	November 2013	15/10/2013	Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hyp ...	Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pu ...	Pulmonary Arterial Hypertension	Drug: BPS-314d-MR	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Lung Biotechnology PBC	Completed	18 Years	75 Years	All	1	Phase 2	United States
3	NCT01908699 (ClinicalTrials.gov)	May 31, 2013	16/7/2013	Beraprost-314d Added-on to Tyvaso® (BEAT)	A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy an ...	Pulmonary Arterial Hypertension	Drug: Beraprost Sodium 314d Modified Release Tablets;Drug: Placebo	Lung Biotechnology PBC	NULL	Completed	18 Years	80 Years	All	273	Phase 3	United States;Israel
4	NCT01458236 (ClinicalTrials.gov)	November 2011	29/9/2011	A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MRin Subjects With ...	A Multinational, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase III Study to Asses ...	Pulmonary Arterial Hypertension	Drug: Beraprost Sodium 314d Modified Release Tablets;Drug: Placebo	Lung Biotechnology Inc.	NULL	Withdrawn	18 Years	80 Years	Both	0	Phase 3	NULL

First Previous1Next Last